End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | Top Midday Gainers | MT |
Financials (USD)
Sales 2024 * | 59.17M | Sales 2025 * | 88.09M | Capitalization | 31.43M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.36 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
7.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |